KR101752124B1 - 선택적인 스핑고신 1 포스페이트 수용체 조절자 및 카이랄 합성 방법 - Google Patents

선택적인 스핑고신 1 포스페이트 수용체 조절자 및 카이랄 합성 방법 Download PDF

Info

Publication number
KR101752124B1
KR101752124B1 KR1020167035297A KR20167035297A KR101752124B1 KR 101752124 B1 KR101752124 B1 KR 101752124B1 KR 1020167035297 A KR1020167035297 A KR 1020167035297A KR 20167035297 A KR20167035297 A KR 20167035297A KR 101752124 B1 KR101752124 B1 KR 101752124B1
Authority
KR
South Korea
Prior art keywords
compound
dihydro
inden
chiral
cyano
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020167035297A
Other languages
English (en)
Korean (ko)
Other versions
KR20160149317A (ko
Inventor
에스더 마틴보로우
마르쿠스 에프. 보헴
아담 리차드 예거
준코 타미야
리밍 황
이누구르티 브라마카리
마니샤 무르자니
그레그 알란 티모니
제니퍼 엘. 브룩스
로버트 피치
피오나 로레인 스콧
마이클 알렌 한슨
Original Assignee
레셉토스,엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43992106&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR101752124(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 레셉토스,엘엘씨 filed Critical 레셉토스,엘엘씨
Publication of KR20160149317A publication Critical patent/KR20160149317A/ko
Application granted granted Critical
Publication of KR101752124B1 publication Critical patent/KR101752124B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/72—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with nitrogen atoms and oxygen or sulfur atoms as ring hetero atoms
    • A01N43/74—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with nitrogen atoms and oxygen or sulfur atoms as ring hetero atoms five-membered rings with one nitrogen atom and either one oxygen atom or one sulfur atom in positions 1,3
    • A01N43/78—1,3-Thiazoles; Hydrogenated 1,3-thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C245/00—Compounds containing chains of at least two nitrogen atoms with at least one nitrogen-to-nitrogen multiple bond
    • C07C245/12—Diazo compounds, i.e. compounds having the free valencies of >N2 groups attached to the same carbon atom
    • C07C245/14—Diazo compounds, i.e. compounds having the free valencies of >N2 groups attached to the same carbon atom having diazo groups bound to acyclic carbon atoms of a carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/58—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/12—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings
    • C07C311/13—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings the carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Plant Pathology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Agronomy & Crop Science (AREA)
  • Pest Control & Pesticides (AREA)
  • Oncology (AREA)
  • Dentistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020167035297A 2009-11-13 2010-11-15 선택적인 스핑고신 1 포스페이트 수용체 조절자 및 카이랄 합성 방법 Active KR101752124B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US26130109P 2009-11-13 2009-11-13
US61/261,301 2009-11-13
US26247409P 2009-11-18 2009-11-18
US61/262,474 2009-11-18
PCT/US2010/056760 WO2011060392A1 (en) 2009-11-13 2010-11-15 Selective sphingosine 1 phosphate receptor modulators and methods of chiral synthesis

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020127015292A Division KR101721716B1 (ko) 2009-11-13 2010-11-15 선택적인 스핑고신 1 포스페이트 수용체 조절자 및 카이랄 합성 방법

Publications (2)

Publication Number Publication Date
KR20160149317A KR20160149317A (ko) 2016-12-27
KR101752124B1 true KR101752124B1 (ko) 2017-06-28

Family

ID=43992106

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020167035297A Active KR101752124B1 (ko) 2009-11-13 2010-11-15 선택적인 스핑고신 1 포스페이트 수용체 조절자 및 카이랄 합성 방법
KR1020127015292A Active KR101721716B1 (ko) 2009-11-13 2010-11-15 선택적인 스핑고신 1 포스페이트 수용체 조절자 및 카이랄 합성 방법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020127015292A Active KR101721716B1 (ko) 2009-11-13 2010-11-15 선택적인 스핑고신 1 포스페이트 수용체 조절자 및 카이랄 합성 방법

Country Status (32)

Country Link
US (4) US8362048B2 (enExample)
EP (3) EP2498610B2 (enExample)
JP (3) JP5650233B2 (enExample)
KR (2) KR101752124B1 (enExample)
CN (2) CN102762100B (enExample)
AU (1) AU2010319983B2 (enExample)
BR (2) BR122018077504B8 (enExample)
CA (2) CA2780772C (enExample)
CY (3) CY1120338T1 (enExample)
DK (2) DK2498610T4 (enExample)
EA (2) EA024801B1 (enExample)
ES (2) ES2673160T5 (enExample)
FI (1) FI2498610T4 (enExample)
FR (1) FR20C1059I2 (enExample)
HR (2) HRP20180874T4 (enExample)
HU (3) HUE037535T2 (enExample)
IL (2) IL219691B (enExample)
LT (3) LT2498610T (enExample)
LU (1) LUC00184I2 (enExample)
MX (1) MX2012005560A (enExample)
MY (2) MY189750A (enExample)
NO (2) NO2498610T3 (enExample)
NZ (1) NZ599915A (enExample)
PH (2) PH12012500939A1 (enExample)
PL (2) PL3406142T3 (enExample)
PT (2) PT3406142T (enExample)
RS (2) RS57253B2 (enExample)
SG (1) SG10201407357PA (enExample)
SI (2) SI2498610T2 (enExample)
SM (2) SMT201800288T1 (enExample)
TR (1) TR201807912T4 (enExample)
WO (1) WO2011060392A1 (enExample)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2780772C (en) 2009-11-13 2018-01-16 Receptos, Inc. Selective sphingosine 1 phosphate receptor modulators and methods of chiral synthesis
PH12012500938A1 (en) * 2009-11-13 2016-09-16 Receptos Llc Sphingosine 1 phosphate receptor modulators and methods of chiral synthesis
JP6129159B2 (ja) 2011-05-13 2017-05-17 レセプトス エルエルシー 選択的複素環式スフィンゴシン１−リン酸受容体モジュレーター
ME02753B (me) * 2012-06-21 2018-01-20 Eisai R&D Man Co Ltd Novi derivati indansulfamida
WO2014158302A1 (en) * 2013-03-25 2014-10-02 Swenson Rolf Eric Novel sphingosine 1-phosphate receptor antagonists
US20170165236A1 (en) * 2013-11-01 2017-06-15 Celgene International Ii Sàrl Selective sphingosine 1 phosphate receptor modulators and combination therapy therewith
CA2981743A1 (en) 2015-04-06 2016-10-13 Auspex Pharmaceuticals, Inc. Deuterium-substituted oxadiazoles
HRP20250558T1 (hr) 2016-06-14 2025-07-04 Receptos Llc Kristalni oblici ozanimoda i ozanimod hidroklorida i procesi za njihovu pripremu
ES2877686T3 (es) * 2016-07-22 2021-11-17 Shijiazhuang Sagacity New Drug Dev Co Ltd Agonista S1P1 y aplicación del mismo
US11028060B2 (en) 2016-08-19 2021-06-08 Receptos Llc Crystalline forms of ozanimod and processes for preparation thereof
US11117875B2 (en) 2016-09-14 2021-09-14 Hangzhou Solipharma Co., Ltd. Crystalline forms, preparation methods and pharmaceutical compositions of ozanimod
US10882830B2 (en) 2016-09-14 2021-01-05 Receptos Llc Crystal form of ozanimod hydrochloride and processes for preparation therefor
WO2018064356A1 (en) 2016-09-29 2018-04-05 Celgene International Ii Sarl Compounds and methods for treating lupus
WO2018157813A1 (zh) * 2017-02-28 2018-09-07 南京明德新药研发股份有限公司 螺环类化合物及其应用
US20200031784A1 (en) * 2017-04-07 2020-01-30 Solipharma Llc Ozanimod addition salt crystal, preparation method, pharmaceutical composition, and uses
CN108727291A (zh) * 2017-04-21 2018-11-02 宁波爱诺医药科技有限公司 奥扎莫德及其中间体的制备方法
CN108727292A (zh) * 2017-04-21 2018-11-02 宁波爱诺医药科技有限公司 一种奥扎莫德及其中间体的制备方法
EP3621610A1 (en) * 2017-05-08 2020-03-18 Celgene International II Sàrl Sphingosine 1 phosphate receptor agonists for neuroprotection
ES2960051T3 (es) 2017-05-22 2024-02-29 Egyt Gyogyszervegyeszeti Gyar Proceso para la producción de ozanimod
US10660879B2 (en) 2017-06-23 2020-05-26 Enzo Biochem, Inc. Sphingosine pathway modulating compounds for the treatment of cancers
WO2018237379A2 (en) 2017-06-23 2018-12-27 Enzo Biochem, Inc. Sphingosine pathway modulating compounds for the treatment of cancers
CN109280035B (zh) * 2017-07-19 2023-06-09 广东东阳光药业有限公司 奥扎莫德的多晶型及其制备方法
EP3677575A4 (en) * 2017-08-31 2020-07-15 Crystal Pharmaceutical (Suzhou) Co., Ltd. CRYSTALLINE FORM OF OZANIMODHYDROCHLORIDE AND PRODUCTION METHOD THEREFOR
WO2019058290A1 (en) * 2017-09-20 2019-03-28 Suven Life Sciences Limited IMPROVED PROCESS FOR THE PREPARATION OF AZANIMOD A-AMINO COMPOUND
WO2019094409A1 (en) 2017-11-07 2019-05-16 Teva Pharmaceuticals International Gmbh Salts and solid state forms of ozanimod
CN107857760A (zh) * 2017-11-21 2018-03-30 南京天翔医药科技有限公司 鞘氨醇‑1‑磷酸受体调节剂及其应用
KR20200128386A (ko) * 2018-01-18 2020-11-12 스자좡 서개시티 뉴 드러그 디벨롭먼트 컴퍼니, 엘티디. 트리사이클릭 화합물의 결정형 및 염 형태, 및 이의 제조방법
CN111801096B (zh) 2018-03-20 2024-03-05 卫材R&D管理有限公司 癫痫治疗剂
CN110615747A (zh) * 2018-06-20 2019-12-27 广东东阳光药业有限公司 一种二氢茚中间体的制备方法
EP3810285B1 (en) 2018-06-25 2025-02-12 Enzo Biochem, Inc. Sphingosine pathway modulating compounds for the treatment of cancers
US20210340115A1 (en) 2018-09-12 2021-11-04 Pharmazell Gmbh A PROCESS FOR THE PREPARATION OF OZANIMOD AND ITS INTERMEDIATE (S)-l-AMINO-2,3-DIHYDRO-1H-INDENE-4-CARBONITRILE
AR116479A1 (es) 2018-09-25 2021-05-12 Quim Sintetica S A Intermediarios para la síntesis de ozanimod y procedimiento para la preparación del mencionado agonista del receptor de esfingosina-1-fosfato y de dichos intermediarios
MX2021006692A (es) 2018-12-07 2021-07-07 Synthon Bv Proceso mejorado para preparar ozanimod.
JP2022527999A (ja) * 2019-03-29 2022-06-07 レセプトス・リミテッド・ライアビリティ・カンパニー スフィンゴシン１リン酸受容体調節因子
KR20210150371A (ko) * 2019-03-29 2021-12-10 리셉토스 엘엘씨 스핑고신 1 포스페이트 수용체 조절제
WO2020205481A1 (en) * 2019-03-29 2020-10-08 Celgene International Ii Sarl Sphingosine 1 phosphate receptor modulators
WO2020219207A1 (en) * 2019-04-26 2020-10-29 Celgene International Ii Sarl Sphingosine 1 phosphate receptor modulator
CN112062785B (zh) * 2019-06-11 2023-06-27 广东东阳光药业有限公司 奥扎莫德及其中间体的制备方法
MX2022000651A (es) 2019-07-16 2022-03-11 Synthon Bv Proceso mejorado para preparar ozanimod.
CN114599363A (zh) 2019-10-31 2022-06-07 爱杜西亚药品有限公司 Cxcr7拮抗剂与s1p1受体调节剂的组合
EP4087562A4 (en) * 2020-01-06 2024-01-10 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the s1p1 receptor
WO2021175225A1 (zh) * 2020-03-04 2021-09-10 南京明德新药研发有限公司 三环类化合物及其应用
EP4545078A3 (en) * 2020-03-04 2025-07-30 Helioeast Pharmaceutical Co., Ltd. Benzo 2-azaspiro[4.4]nonane compound and use thereof
US11554111B2 (en) 2020-03-17 2023-01-17 Enzo Biochem, Inc. Sphingosine pathway modulating compounds for the treatment of coronavirus infection
EP4126829A1 (en) 2020-03-27 2023-02-08 Receptos Llc Sphingosine 1 phosphate receptor modulators
EP4126828A1 (en) * 2020-03-27 2023-02-08 Receptos Llc Sphingosine 1 phosphate receptor modulators
EP4126826A1 (en) 2020-04-02 2023-02-08 Synthon B.V. Crystalline form of ozanimod hydrochloride
CN111620788B (zh) * 2020-04-20 2022-09-30 广东莱佛士制药技术有限公司 一种制备(2s,3s)-3-氨基-二环[2.2.2]辛烷-2-甲酸酯的方法
JP7738667B2 (ja) * 2021-04-09 2025-09-12 ヒーリオイースト ファーマシューティカル カンパニー リミテッド オキサジアゾール置換スピロ環系化合物とその使用
EP4212156A1 (en) 2022-01-13 2023-07-19 Abivax Combination of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine and its derivatives with a s1p receptor modulator
WO2023152767A1 (en) 2022-02-11 2023-08-17 Mylan Laboratories Limited Polymorphic forms of ozanimod hydrochloride
WO2024246174A1 (en) 2023-05-31 2024-12-05 Química Sintética, S.A. Amorphous and crystalline form of ozanimod hydrochloride
WO2025137344A1 (en) 2023-12-20 2025-06-26 Bristol-Myers Squibb Company Antibodies targeting il-18 receptor beta (il-18rβ) and related methods
CN119462405B (zh) * 2025-01-10 2025-05-27 天津阿尔塔科技有限公司 一种氘标记鞘氨醇类化合物和氘标记神经酰胺类化合物的制备方法和应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009151529A1 (en) 2008-05-14 2009-12-17 The Scripps Research Institute Novel modulators of sphingosine phosphate receptors

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1479544A (en) 1974-02-07 1977-07-13 American Cyanamid Co 1,2,3,4-tetrahydro-1-naphthylurea derivatives their preparation and their use
FR2628103B1 (fr) * 1988-03-03 1991-06-14 Roussel Uclaf Nouveaux esters pyrethrinoides portant un noyau indanyle, leur procede de preparation et leur application comme pesticides
US5039802A (en) 1990-04-18 1991-08-13 Merck & Co., Inc. Arylation process for preparation of chiral catalysts for ketone reduction
EP0508425A1 (en) 1991-04-12 1992-10-14 Schering Corporation Bicyclic amides as inhibitors of acyl-coenzyme a: cholesterol acyl transferase
GB2290790A (en) 1994-06-30 1996-01-10 Merck & Co Inc Asymmetric synthesis of 6-substituted 2-amino-1,2,3,4-tetrahydronaphthalenes
DK1057827T3 (da) * 1998-01-23 2004-01-26 Sankyo Co Spiropiperidinderivater
AR035585A1 (es) † 2000-09-15 2004-06-16 Pharmacia Corp Derivados del acido 2-amino-2-alquil-4-heptenoico, composicion farmaceutica y su uso en la fabricacion de medicamentos
US20040058894A1 (en) 2002-01-18 2004-03-25 Doherty George A. Selective S1P1/Edg1 receptor agonists
DE60335827D1 (de) * 2002-12-20 2011-03-03 Merck Sharp & Dohme 1-(amino)indane als edg-rezeptoragonisten
PT3345895T (pt) 2003-04-11 2020-01-29 Ptc Therapeutics Inc Composto de ácido 1,2,4-oxadiazole benzóico e a sua utilização para a supressão sem sentido e tratamento de doenças
US20070043014A1 (en) * 2003-10-01 2007-02-22 Merck & Co., Inc. 3,5-Aryl, heteroaryl or cycloalkyl substituted-1,2,4-oxadiazoles as s1p receptor agonists
AU2004299456B2 (en) * 2003-12-17 2010-10-07 Merck Sharp & Dohme Corp. (3,4-disubstituted)propanoic carboxylates as S1P (Edg) receptor agonists
US7585881B2 (en) * 2004-02-18 2009-09-08 Astrazeneca Ab Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
US20060173183A1 (en) 2004-12-31 2006-08-03 Alantos Pharmaceuticals, Inc., Multicyclic bis-amide MMP inhibitors
AU2006245349A1 (en) 2005-02-22 2006-11-16 Teva Pharmaceutical Industries Ltd. Improved process for the synthesis of enantiomeric indanylamine derivatives
KR100667075B1 (ko) 2005-07-22 2007-01-10 삼성에스디아이 주식회사 주사 구동부 및 이를 포함하는 유기 전계발광 표시장치
EP1912640B1 (en) † 2005-08-03 2015-06-17 Novartis AG Use of the hdac inhibitor panobinostat for the treatment of myeloma
US7582803B2 (en) 2005-09-14 2009-09-01 Amgen Inc. Conformationally constrained 3-(4-hydroxy-phenyl)-substituted-propanoic acids useful for treating metabolic disorders
PE20070705A1 (es) * 2005-11-25 2007-08-23 Basf Ag Compuestos de indanil - y tetrahidronaftil-amino-azolina para combatir pestes animales
US7902336B2 (en) 2005-12-21 2011-03-08 Joseph Gabriele Catecholamine regulated protein
CA2643055A1 (en) 2006-03-13 2007-09-20 Pfizer Products Inc. Tetralines antagonists of the h-3 receptor
US20080009534A1 (en) * 2006-07-07 2008-01-10 Bristol-Myers Squibb Company Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
CN101522645B (zh) * 2006-09-21 2013-01-09 埃科特莱茵药品有限公司 苯衍生物及其免疫调节剂的用途
JP2010510250A (ja) 2006-11-21 2010-04-02 ユニバーシティ オブ バージニア パテント ファンデーション スフィンゴシン＝１−燐酸受容体アゴニスト活性を有するヒドリンダンアナログ
MX2009006304A (es) * 2006-12-15 2009-06-23 Abbott Lab Nuevos compuestos de oxadiazol.
JO2701B1 (en) 2006-12-21 2013-03-03 جلاكسو جروب ليميتد Vehicles
WO2008106226A2 (en) 2007-02-28 2008-09-04 Rib-X Pharmaceuticals, Inc. Macrolide compounds and methods of making and using the same
GB0725104D0 (en) 2007-12-21 2008-01-30 Glaxo Group Ltd Compounds
US20090298894A1 (en) 2008-04-21 2009-12-03 Asahi Kasei Pharma Corporation Amino acid compounds
US8485794B2 (en) * 2008-06-13 2013-07-16 Doowon Technical College Reciprocating compressor with rotary valve
GB0910674D0 (en) 2009-06-19 2009-08-05 Glaxo Group Ltd Novel compounds
WO2011005290A1 (en) 2009-06-23 2011-01-13 Arena Pharmaceuticals, Inc. Disubstituted oxadiazole derivatives useful in the treatment of autoimmune and inflammatory disorders
GB0911130D0 (en) 2009-06-26 2009-08-12 Glaxo Group Ltd Novel compounds
PT2498609T (pt) 2009-11-13 2018-07-06 Celgene Int Ii Sarl Moduladores de recetor de esfingosina 1 fosfato heterocíclico seletivo
PH12012500938A1 (en) * 2009-11-13 2016-09-16 Receptos Llc Sphingosine 1 phosphate receptor modulators and methods of chiral synthesis
CA2780772C (en) 2009-11-13 2018-01-16 Receptos, Inc. Selective sphingosine 1 phosphate receptor modulators and methods of chiral synthesis
JP6129159B2 (ja) 2011-05-13 2017-05-17 レセプトス エルエルシー 選択的複素環式スフィンゴシン１−リン酸受容体モジュレーター
KR20140101333A (ko) 2011-10-12 2014-08-19 테바 파마슈티컬 인더스트리즈 리미티드 라퀴니모드 및 핑골리모드의 조합을 이용한 다발성 경화증의 치료

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009151529A1 (en) 2008-05-14 2009-12-17 The Scripps Research Institute Novel modulators of sphingosine phosphate receptors

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
J Org Chem., 2006.09., Vol.71, No.18., pp 6859-6862
J Org Chem., 2007.01., Vol.72, No.2., pp 626-629

Also Published As

Publication number Publication date
EP3406142B1 (en) 2020-12-23
EP2498610A1 (en) 2012-09-19
FR20C1059I1 (enExample) 2020-12-25
ES2673160T3 (es) 2018-06-20
BR122018077504B8 (pt) 2021-05-25
CA2986521C (en) 2020-06-30
HRP20180874T4 (hr) 2024-09-27
FI2498610T4 (fi) 2024-08-29
ES2673160T5 (es) 2024-11-19
PT3406142T (pt) 2021-03-26
PL2498610T5 (pl) 2024-11-04
CY1120338T1 (el) 2019-07-10
PT2498610T (pt) 2018-06-19
BR112012011427A2 (pt) 2015-10-06
US10239846B2 (en) 2019-03-26
HRP20180874T1 (hr) 2018-07-13
IL267956A (en) 2019-09-26
SI2498610T2 (sl) 2024-10-30
EA024801B1 (ru) 2016-10-31
US20150299149A1 (en) 2015-10-22
KR20160149317A (ko) 2016-12-27
PH12012500939A1 (en) 2016-06-15
LUC00184I2 (enExample) 2024-07-01
US20170320839A1 (en) 2017-11-09
JP2015038145A (ja) 2015-02-26
CN102762100A (zh) 2012-10-31
IL219691A0 (en) 2012-07-31
RS61829B1 (sr) 2021-06-30
FR20C1059I2 (fr) 2021-12-10
PL3406142T3 (pl) 2021-08-30
AU2010319983A1 (en) 2012-05-31
KR20120102704A (ko) 2012-09-18
CY2020035I1 (el) 2021-03-12
EP2498610B2 (en) 2024-06-19
BR122018077504B1 (pt) 2021-05-11
EA201690391A1 (ru) 2016-08-31
HK1213874A1 (zh) 2016-07-15
HUE054000T2 (hu) 2021-08-30
EA201290323A1 (ru) 2013-05-30
SI2498610T1 (en) 2018-07-31
EP3868377A1 (en) 2021-08-25
DK2498610T3 (en) 2018-06-14
HUE037535T2 (hu) 2018-09-28
SMT202100169T1 (it) 2021-07-12
US20110172202A1 (en) 2011-07-14
PH12015502708A1 (en) 2016-10-17
HRP20210446T1 (hr) 2021-05-14
MX2012005560A (es) 2012-10-05
MY161854A (en) 2017-05-15
JP5982705B2 (ja) 2016-08-31
DK2498610T4 (da) 2024-09-09
NZ599915A (en) 2014-07-25
LT2498610T (lt) 2018-06-11
EP3406142A1 (en) 2018-11-28
SI3406142T1 (sl) 2021-08-31
CA2780772C (en) 2018-01-16
BR112012011427B8 (pt) 2021-05-25
SMT201800288T1 (it) 2018-07-17
RS57253B2 (sr) 2024-10-31
NO2498610T3 (enExample) 2018-08-11
MY189750A (en) 2022-03-02
IL267956B (en) 2021-01-31
RS57253B1 (sr) 2018-08-31
US20130231326A1 (en) 2013-09-05
LTC2498610I2 (lt) 2022-06-10
LT3406142T (lt) 2021-06-10
HUS2000045I1 (hu) 2020-12-28
CN105061350B (zh) 2018-05-29
US8362048B2 (en) 2013-01-29
CY2020035I2 (el) 2021-03-12
ES2858337T3 (es) 2021-09-30
US9388147B2 (en) 2016-07-12
PL2498610T3 (pl) 2018-08-31
CA2780772A1 (en) 2011-05-19
DK3406142T3 (da) 2021-03-22
HK1175948A1 (en) 2013-07-19
TR201807912T4 (tr) 2018-06-21
LTPA2020533I1 (lt) 2020-12-10
CN105061350A (zh) 2015-11-18
IL219691B (en) 2019-07-31
EP2498610A4 (en) 2013-05-22
AU2010319983A2 (en) 2013-09-12
JP5650233B2 (ja) 2015-01-07
BR112012011427B1 (pt) 2021-04-20
EP3406142B8 (en) 2021-03-03
WO2011060392A1 (en) 2011-05-19
KR101721716B1 (ko) 2017-04-10
CA2986521A1 (en) 2011-05-19
EP2498610B1 (en) 2018-03-14
JP2013510885A (ja) 2013-03-28
JP2014122208A (ja) 2014-07-03
SG10201407357PA (en) 2014-12-30
AU2010319983B2 (en) 2015-03-12
EA035768B1 (ru) 2020-08-07
CN102762100B (zh) 2015-07-01
NO2020039I1 (no) 2020-11-18
CY1124121T1 (el) 2022-05-27
PH12015502708B1 (en) 2018-06-06

Similar Documents

Publication Publication Date Title
KR101752124B1 (ko) 선택적인 스핑고신 1 포스페이트 수용체 조절자 및 카이랄 합성 방법
KR101781233B1 (ko) 스핑고신 1 포스페이트 수용체 조절자 및 카이랄 합성 방법
KR101771755B1 (ko) 선택적 헤테로시클릭 스핑고신 1 포스페이트 수용체 조절자
WO2015066515A1 (en) Selective sphingosine 1 phosphate receptor modulators and combination therapy therewith
AU2015202660B2 (en) Selective sphingosine 1 phosphate receptor modulators and methods of chiral synthesis
HK1175948B (en) Selective sphingosine 1 phosphate receptor modulators and methods of chiral synthesis
HK1213874B (en) Selective sphingosine 1 phosphate receptor modulators and methods of chiral synthesis

Legal Events

Date Code Title Description
A107 Divisional application of patent
A201 Request for examination
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20161216

Application number text: 1020127015292

Filing date: 20120613

PA0201 Request for examination
PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20170110

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20170517

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20170622

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20170622

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20200612

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20210527

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee

Payment date: 20220517

Start annual number: 6

End annual number: 6

PR1001 Payment of annual fee

Payment date: 20230518

Start annual number: 7

End annual number: 7

PR1001 Payment of annual fee

Payment date: 20240522

Start annual number: 8

End annual number: 8